Compounds > chloroquine
Page last updated: 2024-10-24

chloroquine and Infections, Coronavirus

chloroquine has been researched along with Infections, Coronavirus in 273 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Research Excerpts

ExcerptRelevanceReference
"Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades."9.05Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. ( Chen, ZS; Dong, S; Ke, Z; Lei, ZN; Wu, ZX; Yang, DH; Zhang, L; Zou, C, 2020)
"On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning."9.05Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020)
"The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy."7.96Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020)
"Malaria is a threat to human mankind and kills about half a million people every year."6.66Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. ( de Souza, EE; Guimarães, LMF; Krüger, A; Lameu, C; Pillat, MM; Ulrich, H; Wrenger, C, 2020)
"Chloroquine has been sporadically used in treating SARS-CoV-2 infection."5.56In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020)
" The primary outcomes include Sputum virus nucleic acid negative time, lung imaging improvement time, mortality rate, mechanical ventilation rate, ICU hospitalization time, hospitalization time, clinical improvement, symptoms Improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc."5.56Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020)
"Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades."5.05Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. ( Chen, ZS; Dong, S; Ke, Z; Lei, ZN; Wu, ZX; Yang, DH; Zhang, L; Zou, C, 2020)
"Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug."5.05Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. ( Knibbe, CAJ; Peeters, MYM; Smit, C; van den Anker, JN, 2020)
"On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning."5.05Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. ( Alhatali, B; Berling, I; Ghannoum, M; Gosselin, S; Hoffman, RS; King, JD; Lavergne, V; Nolin, TD; Roberts, DM; Shepherd, G; Wilson, G, 2020)
"Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment."3.96Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020)
"Neither diazepam nor other ligands for benzodiazepine binding sites protect against or attenuate chloroquine cardiotoxicity."3.96Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam. ( Hughes, DA, 2020)
"The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy."3.96Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020)
"The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir."2.94Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. ( Albuquerque, BC; Alexandre, MAA; Baía-da-Silva, D; Balieiro, AAS; Bassat, Q; Borba, MGS; Brito, M; Brito-Sousa, JD; Croda, J; Daniel-Ribeiro, CT; Fontes, CJ; Guerra, MVF; Hajjar, LA; Lacerda, MVG; Melo, GC; Monteiro, WM; Mourão, MPG; Naveca, FG; Nogueira, ML; Pacheco, AGF; Pinto, RC; Romero, GAS; Sampaio, VS; Santos, JDO; Schwarzbold, A; Siqueira, AM; Val, FFA; Xavier, MS, 2020)
"Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial."2.94[Chloroquine phosphate: therapeutic drug for COVID-19]. ( Mo, L; Zheng, P, 2020)
" The current dosage recommended in clinical treatment is larger than that in previous treatment of malaria and the period of treatment is longer."2.66Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology. ( Duan, YJ; Huang, F; Liu, L; Liu, Q; Ren, L; Zhao, SQ; Zhou, YW, 2020)
"As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy."2.66Current status of potential therapeutic candidates for the COVID-19 crisis. ( Hashimoto, K; Xie, B; Zhang, J, 2020)
"Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended."2.66Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. ( Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM, 2020)
"Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic."2.66Medical treatment options for COVID-19. ( Delang, L; Neyts, J, 2020)
" However, some of these medications have potential cardiac adverse effects."2.66Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020)
"Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro."2.66Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. ( Akram, J; Klonoff, DC; Meo, SA, 2020)
"Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system."2.66A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020)
" The review elaborates the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine to benefit the clinicians, medicinal chemist, pharmacologist actively involved in controlling the pandemic and to provide therapeutics for the treatment of COVID-19 infection."2.66A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. ( Masand, N; Patil, VM; Singhal, S, 2020)
" Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease."2.66The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? ( Biasiotto, G; Magro, P; Quiros Roldan, E; Zanella, I, 2020)
"Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine."2.66[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. ( Baranchuk, A; Barbosa, M; Márquez, MF; Mendoza, I; Nuñez, E; Sosa Liprandi, Á; Wyss Quintana, FS; Zaidel, EJ, 2020)
"The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019."2.66Is hydroxychloroquine beneficial for COVID-19 patients? ( Agostinis, P; Carafoli, E; Li, X; Melino, G; Rabson, A; Shi, Y; Sun, E; Wang, Y, 2020)
"Chloroquine has recently been shown to be effective in controlling infection caused by the new Corona virus 2019- nCov (SARS-CoV-2)."2.66Chloroquine in controlling biological infections. ( Baranowska, A; Krawczyk, J; Lengier-Krajewska, M; Płusa, T, 2020)
"Chloroquine has been used to treat malaria for more than 70 years."2.66Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. ( Cui, C; Hou, Z; Li, H; Liu, D; Tu, S; Yao, X; Zhang, M, 2020)
"Malaria is a threat to human mankind and kills about half a million people every year."2.66Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. ( de Souza, EE; Guimarães, LMF; Krüger, A; Lameu, C; Pillat, MM; Ulrich, H; Wrenger, C, 2020)
" Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders."2.66Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. ( Khuroo, MS, 2020)
"The emergence of coronavirus disease 2019 (COVID-19) in December 2019 has resulted in over 20 million cases and 741,808 deaths globally, affecting more than 200 countries."2.66Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. ( Adewale, OB; Akanbi, MO; Bakare, OO; Fadaka, AO; Klein, A; Madiehe, AM; Meyer, M; Sibuyi, NRS, 2020)
"Sarcoidosis is an autoinflammatory disease characterized by the diffusion of granulomas in the lungs and other organs."2.66Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. ( Calender, A; Israel-Biet, D; Pacheco, Y; Valeyre, D, 2020)
"The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world."2.66The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020)
"COVID-19 (coronavirus disease 2019) is a public health emergency of international concern."2.66A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. ( Cortegiani, A; Einav, S; Giarratano, A; Ingoglia, G; Ippolito, M, 2020)
"Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide."2.66Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. ( Hsueh, PR; Hsueh, SC; Ko, WC; Lai, CC; Liu, YH; Wang, CY; Wang, YH; Yen, MY, 2020)
"During the current coronavirus disease 2019 (COVID-19) pandemic, in vivo and in vitro investigations of these drugs have demonstrated potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."2.66Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals. ( Ahmad, A; Alotaibi, NH; Butt, MH; Khan, YH; Mallhi, TH; Misbah, S, 2020)
"The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients."1.56Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. ( Alwayn, IPJ; de Fijter, JW; de Vries, APJ; Janson, JA; Meziyerh, S; Moes, DJAR; Reinders, MEJ; van Etten, RW; van Gelder, T; Zwart, TC, 2020)
"Chloroquine has been proved clinically effective and can bind to the main protease; this may be the antiviral mechanism of this drug."1.56Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. ( Chen, L; Lan, R; Li, P; Shen, R; Yu, R, 2020)
" This position statement recommends dosage adjustment for these drugs in the context of renal impairment."1.56Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. ( Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020)
"Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria."1.56Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. ( Abena, PM; Adejumo, P; Bottieau, E; Decloedt, EH; Eholie, SP; Kallay, O; Mills, EJ; Muyembe TamFum, JJ; Nachega, JB; Sam-Agudu, NA; Seydi, M; Suleman, F; Zumla, A, 2020)
"To the Editor The Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by World Health Organisation (WHO)."1.56Chloroquine in COVID-19: the evidence. ( Agrawal, S; Gupta, N; Ish, P, 2020)
"SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans."1.56New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? ( Colson, P; Devaux, CA; Raoult, D; Rolain, JM, 2020)
" The primary outcomes include Sputum virus nucleic acid negative time, lung imaging improvement time, mortality rate, mechanical ventilation rate, ICU hospitalization time, hospitalization time, clinical improvement, symptoms Improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc."1.56Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020)
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."1.565-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. ( Ahmad, SI, 2020)
"In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported."1.56Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. ( Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J, 2020)
"Chloroquine has been sporadically used in treating SARS-CoV-2 infection."1.56In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020)
" The potential for the use of smart drug delivery technologies like nanoparticle drones loaded with these phytomedicines to overcome bioavailability limitations and improve therapeutic efficacy are discussed."1.56Potential of Flavonoid-Inspired Phytomedicines against COVID-19. ( Kumar, R; Lowe, H; Lyerly, W; Moore, R; Ngwa, W; Reid, TE; Thompson, D; Toyang, N, 2020)
" In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ."1.56Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. ( Abagyan, R; Cohen, IV; Issa, MA; Makunts, T; Moumedjian, T, 2020)
" Therefore, rOC43-ns2DelRluc represents a promising safe and sensitive platform for high-throughput antiviral screening and quantitative analysis of viral replication."1.43Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene. ( Desforges, M; Liu, G; Shen, L; Talbot, PJ; Tan, W; Yang, Y; Ye, F, 2016)

Research

Studies (273)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (0.37)29.6817
2010's2 (0.73)24.3611
2020's270 (98.90)2.80

Authors

AuthorsStudies
Gordon, DE1
Jang, GM1
Bouhaddou, M1
Xu, J1
Obernier, K1
White, KM1
O'Meara, MJ1
Rezelj, VV1
Guo, JZ1
Swaney, DL1
Tummino, TA1
Hüttenhain, R1
Kaake, RM1
Richards, AL1
Tutuncuoglu, B1
Foussard, H1
Batra, J1
Haas, K1
Modak, M1
Kim, M1
Haas, P1
Polacco, BJ1
Braberg, H1
Fabius, JM1
Eckhardt, M1
Soucheray, M1
Bennett, MJ1
Cakir, M1
McGregor, MJ1
Li, Q2
Meyer, B1
Roesch, F1
Vallet, T1
Mac Kain, A1
Miorin, L1
Moreno, E1
Naing, ZZC1
Zhou, Y2
Peng, S1
Shi, Y4
Zhang, Z3
Shen, W1
Kirby, IT1
Melnyk, JE1
Chorba, JS1
Lou, K1
Dai, SA1
Barrio-Hernandez, I1
Memon, D1
Hernandez-Armenta, C1
Lyu, J1
Mathy, CJP1
Perica, T1
Pilla, KB1
Ganesan, SJ1
Saltzberg, DJ1
Rakesh, R1
Liu, X4
Rosenthal, SB1
Calviello, L1
Venkataramanan, S1
Liboy-Lugo, J1
Lin, Y2
Huang, XP1
Liu, Y6
Wankowicz, SA1
Bohn, M1
Safari, M1
Ugur, FS1
Koh, C1
Savar, NS1
Tran, QD1
Shengjuler, D1
Fletcher, SJ1
O'Neal, MC1
Cai, Y2
Chang, JCJ1
Broadhurst, DJ1
Klippsten, S1
Sharp, PP1
Wenzell, NA1
Kuzuoglu-Ozturk, D1
Wang, HY1
Trenker, R1
Young, JM1
Cavero, DA1
Hiatt, J1
Roth, TL1
Rathore, U1
Subramanian, A1
Noack, J1
Hubert, M1
Stroud, RM1
Frankel, AD1
Rosenberg, OS1
Verba, KA1
Agard, DA1
Ott, M1
Emerman, M1
Jura, N1
von Zastrow, M1
Verdin, E1
Ashworth, A1
Schwartz, O1
d'Enfert, C1
Mukherjee, S2
Jacobson, M1
Malik, HS1
Fujimori, DG1
Ideker, T1
Craik, CS1
Floor, SN1
Fraser, JS1
Gross, JD1
Sali, A1
Roth, BL1
Ruggero, D1
Taunton, J1
Kortemme, T1
Beltrao, P1
Vignuzzi, M1
García-Sastre, A1
Shokat, KM1
Shoichet, BK1
Krogan, NJ1
Jeon, S1
Ko, M1
Lee, J1
Choi, I1
Byun, SY1
Park, S2
Shum, D1
Kim, S2
Chotsiri, P1
Tarning, J3
Hoglund, RM3
Watson, JA3
White, NJ3
Hickerson, BT1
Sheikh, F1
Donnelly, RP1
Ilyushina, NA1
Niu, J1
Shen, L3
Huang, B2
Ye, F3
Zhao, L2
Wang, H3
Deng, Y2
Tan, W3
Wang, M1
Cao, R1
Zhang, L6
Yang, X4
Liu, J2
Xu, M1
Shi, Z1
Hu, Z1
Zhong, W1
Xiao, G1
Colson, P3
Rolain, JM3
Raoult, D4
Maxmen, A1
Gao, J4
Tian, Z1
Zhang, Q4
Wang, Y7
Qi, C1
Li, J8
Lagier, JC1
Brouqui, P1
Touret, F1
de Lamballerie, X1
Dong, L2
Hu, S3
Yao, X2
Zhang, M6
Cui, C2
Niu, P1
Dong, E1
Song, C1
Zhan, S1
Lu, R1
Li, H6
Liu, D2
Zhu, LQ1
Nau, JY1
Devaux, CA1
Cortegiani, A3
Ingoglia, G3
Ippolito, M3
Giarratano, A2
Einav, S3
Lai, CC1
Liu, YH1
Wang, CY1
Wang, YH1
Hsueh, SC1
Yen, MY1
Ko, WC1
Hsueh, PR1
Sahraei, Z1
Shabani, M1
Shokouhi, S1
Saffaei, A1
Duan, Y1
Zhu, HL1
Zhou, C1
Hu, TY1
Frieman, M1
Wolfram, J1
Guastalegname, M1
Vallone, A1
Duan, YJ1
Liu, Q2
Zhao, SQ1
Huang, F1
Ren, L1
Liu, L3
Zhou, YW1
Carradori, S1
Lecuit, M1
Kupferschmidt, K2
Cohen, J1
Zhang, W1
Zhao, Y4
Zhang, F3
Wang, Q3
Li, T1
Liu, Z4
Wang, J6
Qin, Y1
Zhang, X6
Yan, X1
Zeng, X1
Zhang, S3
Agrawal, S2
Goel, AD1
Gupta, N2
Ish, P2
Yazdany, J1
Kim, AHJ1
Georgiev, T1
Hong, W1
Huang, M2
Tang, T1
Pang, P1
Li, M2
Ma, R1
Lu, J5
Shu, J1
You, Y1
Chen, B2
Liang, J1
Hong, Z2
Chen, H3
Kong, L1
Qin, D1
Pei, D1
Xia, J2
Jiang, S1
Shan, H1
Spinelli, FR1
Ceccarelli, F1
Di Franco, M2
Conti, F2
Keshtkar-Jahromi, M1
Bavari, S1
Marmor, MF2
Marotto, D1
Sarzi-Puttini, P1
Fantini, J1
Di Scala, C1
Chahinian, H1
Yahi, N1
Barlow, A1
Landolf, KM1
Barlow, B1
Yeung, SYA1
Heavner, JJ1
Claassen, CW1
Heavner, MS1
Moore, N1
Monteiro, WM2
Brito-Sousa, JD2
Baía-da-Silva, D2
Melo, GC2
Siqueira, AM2
Val, F1
Daniel-Ribeiro, CT2
Guimarães Lacerda, MV1
Juurlink, DN1
Ferner, RE1
Aronson, JK1
Jakhar, D1
Kaur, I1
Jaffe, S1
Serafin, MB1
Bottega, A1
Foletto, VS1
da Rosa, TF1
Hörner, A1
Hörner, R1
Shah, S1
Das, S2
Jain, A1
Misra, DP1
Negi, VS1
Kassi, EN1
Papavassiliou, KA1
Papavassiliou, AG1
Sanders, JM1
Monogue, ML1
Jodlowski, TZ1
Cutrell, JB1
Guidon, AC1
Amato, AA1
Rome, BN1
Avorn, J1
Şimşek Yavuz, S1
Ünal, S1
Gendrot, M1
Javelle, E1
Clerc, A1
Savini, H1
Pradines, B1
El Boussadani, B1
Benajiba, C1
Aajal, A1
Ait Brik, A1
Ammour, O1
El Hangouch, J1
Oussama, O1
Oussama, B1
Tahiri, N1
Raissuni, Z1
Zhao, M1
Smit, C1
Peeters, MYM1
van den Anker, JN1
Knibbe, CAJ1
Principi, N1
Esposito, S1
Rathi, S1
Kalantri, A1
Kalantri, S1
Lentini, G1
Cavalluzzi, MM1
Habtemariam, S2
Perricone, C1
Triggianese, P1
Bartoloni, E1
Cafaro, G1
Bonifacio, AF1
Bursi, R1
Perricone, R1
Gerli, R1
Dondorp, AM1
Hayat, M1
Aryal, D1
Beane, A1
Schultz, MJ1
Verscheijden, LFM1
van der Zanden, TM1
van Bussel, LPM1
de Hoop-Sommen, M1
Russel, FGM1
Johnson, TN1
de Wildt, SN1
Licciardi, F1
Giani, T1
Baldini, L1
Favalli, EG1
Caporali, R1
Cimaz, R1
Embi, MN1
Ganesan, N1
Sidek, HM1
Abena, PM1
Decloedt, EH2
Bottieau, E1
Suleman, F1
Adejumo, P1
Sam-Agudu, NA1
Muyembe TamFum, JJ1
Seydi, M1
Eholie, SP1
Mills, EJ1
Kallay, O1
Zumla, A1
Nachega, JB1
Manning, TJ1
Thomas-Richardson, J1
Cowan, M1
Beard, T1
Zhao, X1
Jiang, Y2
Xi, H1
Liu, C5
Qu, F1
Feng, X2
Fihn, SD1
Perencevich, E1
Bradley, SM1
Borba, MGS1
Val, FFA1
Sampaio, VS1
Alexandre, MAA1
Brito, M1
Mourão, MPG1
Guerra, MVF1
Hajjar, LA1
Pinto, RC1
Balieiro, AAS1
Pacheco, AGF1
Santos, JDO1
Naveca, FG1
Xavier, MS1
Schwarzbold, A1
Croda, J1
Nogueira, ML1
Romero, GAS1
Bassat, Q1
Fontes, CJ1
Albuquerque, BC1
Lacerda, MVG1
Alexander, PE1
Debono, VB1
Mammen, MJ1
Iorio, A1
Aryal, K1
Deng, D1
Brocard, E1
Alhazzani, W1
Millán-Oñate, J1
Millan, W1
Mendoza, LA1
Sánchez, CG1
Fernandez-Suarez, H1
Bonilla-Aldana, DK1
Rodríguez-Morales, AJ1
Funck-Brentano, C1
Salem, JE1
Nguyen, LS1
Drici, MD1
Roden, DM1
Cheng, CY1
Lee, YL1
Chen, CP1
Lin, YC1
Liu, CE1
Liao, CH1
Cheng, SH1
Ledford, H2
Capoluongo, ED1
Amato, F1
Castaldo, G1
Zhang, J6
Xie, B1
Hashimoto, K1
Iyer, M1
Jayaramayya, K1
Subramaniam, MD1
Lee, SB2
Dayem, AA1
Cho, SG1
Vellingiri, B1
Ahsan, W1
Javed, S1
Bratty, MA1
Alhazmi, HA1
Najmi, A1
Meziyerh, S1
Zwart, TC1
van Etten, RW1
Janson, JA1
van Gelder, T1
Alwayn, IPJ1
de Fijter, JW1
Reinders, MEJ1
Moes, DJAR1
de Vries, APJ1
Askanase, AD1
Khalili, L1
Buyon, JP1
Sargin, G1
Yavaşoğlu, Sİ1
Yavasoglu, I1
Saleh, M1
Gabriels, J1
Chang, D1
Soo Kim, B1
Mansoor, A1
Mahmood, E1
Makker, P1
Ismail, H1
Goldner, B1
Willner, J1
Beldner, S1
Mitra, R1
John, R1
Chinitz, J1
Skipitaris, N1
Mountantonakis, S1
Epstein, LM1
Liu, M1
Caputi, TL1
Dredze, M1
Kesselheim, AS2
Ayers, JW1
Jeevaratnam, K1
Javelot, H1
El-Hage, W1
Meyer, G1
Becker, G1
Michel, B1
Hingray, C1
Kang, Y1
Chen, T1
Mui, D1
Ferrari, V1
Jagasia, D1
Scherrer-Crosbie, M1
Chen, Y6
Han, Y1
Chary, MA1
Barbuto, AF1
Izadmehr, S1
Hayes, BD1
Burns, MM1
Monzani, A1
Genoni, G1
Scopinaro, A1
Pistis, G1
Kozel, D1
Secco, GG1
Chowdhury, MS1
Rathod, J1
Gernsheimer, J1
Shader, RI1
Delang, L1
Neyts, J2
Xu, CY1
Lu, SD1
Ye, X1
Cao, MY1
Xu, GD1
Yu, Q1
Qian, JX1
Zeng, G1
Svensson, M1
Seftel, MD1
Nath, KA1
D'Acquarica, I1
Agranat, I1
Naksuk, N1
Lazar, S1
Peeraphatdit, TB1
Meo, SA1
Klonoff, DC1
Akram, J1
Lucchino, B1
Wong, A1
Szekely, Y1
Lichter, Y1
Shrkihe, BA1
Bruck, H1
Oster, HS1
Viskin, S1
Piszczatoski, CR1
Powell, J1
Yu, R1
Chen, L4
Lan, R1
Shen, R2
Li, P2
Kuipers, MT1
van Zwieten, R1
Heijmans, J1
Rutten, CE1
de Heer, K1
Kater, AP1
Nur, E1
Coumou, J1
de Vries, PJ1
Annangi, S1
Gadebusch Bondio, M1
Marloth, M1
Anastasiou, IA1
Eleftheriadou, I1
Tentolouris, A1
Tsilingiris, D1
Tentolouris, N1
Gnegel, G1
Hauk, C1
Neci, R1
Mutombo, G1
Nyaah, F1
Wistuba, D1
Häfele-Abah, C1
Heide, L1
Palmeira, VA1
Costa, LB1
Perez, LG1
Ribeiro, VT1
Lanza, K1
Silva, ACSE1
Derwand, R1
Scholz, M1
Gegúndez-Fernández, JA1
Zarranz-Ventura, J1
Garay-Aramburu, G1
Muñoz-Negrete, FJ1
Mendicute Del Barrio, J1
Pablo-Júlvez, L1
García-Delpech, S1
López-Alemany, A1
Arnalich-Montiel, F1
Cordero-Coma, M1
Cárceles, JA1
Hughes, DA1
Asensio, E1
Acunzo, R1
Uribe, W1
Saad, EB1
Sáenz, LC1
Patil, VM1
Singhal, S1
Masand, N1
Qaseem, A3
Yost, J3
Etxeandia-Ikobaltzeta, I3
Miller, MC2
Abraham, GM2
Obley, AJ2
Forciea, MA2
Jokela, JA2
Humphrey, LL3
Centor, RM1
Andrews, R1
Bledsoe, TA1
Haeme, R1
Kansagara, DL1
Marcucci, M1
Gevers, S1
Kwa, MSG1
Wijnans, E1
van Nieuwkoop, C1
Estella, Á1
Garnacho-Montero, J1
Marto, N1
Monteiro, EC1
Kucharz, EJ1
Zhai, MZ1
Lye, CT1
Quiros Roldan, E1
Biasiotto, G1
Magro, P1
Zanella, I1
Oren, O1
Yang, EH1
Gluckman, TJ1
Michos, ED1
Blumenthal, RS1
Gersh, BJ1
Edelstein, CL1
Venkatachalam, MA1
Dong, Z2
Ahmad, SI1
Yahya, AS1
Khawaja, S1
Chukwuma, J1
Zaidel, EJ1
Wyss Quintana, FS1
Sosa Liprandi, Á1
Mendoza, I1
Márquez, MF1
Nuñez, E1
Barbosa, M1
Baranchuk, A1
Tripathy, S1
Dassarma, B1
Roy, S1
Chabalala, H1
Matsabisa, MG1
Thangaraju, P1
Gurunthalingam, MP1
Venkatesan, S1
Thangaraju, E1
Gao, Q1
Hernandez, AV5
Roman, YM4
Pasupuleti, V4
Barboza, JJ4
White, CM5
Hodkinson, B1
Singh, P1
Gcelu, A1
Bautista-Molano, W1
Pons-Estel, G1
Alpízar-Rodríguez, D1
Kamp, TJ1
Hamdan, MH1
January, CT1
Vaduganathan, M1
van Meijgaard, J1
Mehra, MR1
Joseph, J1
O'Donnell, CJ1
Warraich, HJ1
Rodrigo, C1
Fernando, SD1
Rajapakse, S1
Lahfaoui, M1
Azizi, M1
Elbakkaoui, M1
El Amrani, R1
Kamaoui, I1
Benhaddou, H1
Ektorp, E1
Weehuizen, JM1
Hoepelman, AIM1
Askin, L1
Tanrıverdi, O1
Askin, HS1
Liu, W1
Zhou, P1
Chen, K2
Ye, Z1
Liu, F1
Li, X14
He, N1
Wu, Z1
Gong, X1
Tang, Q1
Du, X2
Ying, Y1
Xu, X3
Zhang, Y7
Li, Y7
Shen, N1
Couban, RJ1
Ibrahim, QI1
Guyatt, G1
Zhai, S1
Ibáñez, S1
Martínez, O1
Valenzuela, F1
Silva, F1
Valenzuela, O1
Sun, J2
Fan, X1
Wang, X12
Han, Q1
Lang, JP1
Moura, FA1
Siddiqi, HK1
Morrow, DA1
Bohula, EA1
Mvumbi, DM1
Gouveia, CC1
Campos, L1
Bimonte, S1
Crispo, A1
Amore, A1
Celentano, E1
Cuomo, A1
Cascella, M1
Ata, F1
Almasri, H1
Sajid, J1
Yousaf, Z1
Dos Reis Neto, ET1
Kakehasi, AM1
de Medeiros Pinheiro, M1
Ferreira, GA1
Marques, CDL1
da Mota, LMH1
Dos Santos Paiva, E1
Pileggi, GCS1
Sato, EI1
Reis, APMG1
Xavier, RM1
Provenza, JR1
Nowak, JK3
Walkowiak, J3
Medeiros-Domingo, A1
Carrasco, OF1
Berni-Betancourt, A1
Pan, X2
Yang, L1
Chen, D2
Peng, C1
Medina, MT1
Moncada, SS1
Santillán-García, A1
Bravo-Jeria, R1
Verdugo-Paiva, F1
Rada, G1
Ngwa, W1
Kumar, R1
Thompson, D1
Lyerly, W1
Moore, R1
Reid, TE1
Lowe, H1
Toyang, N1
Huang, Y2
Cai, C1
Zang, J1
Xie, J1
Xu, D1
Zheng, F1
Zhan, T1
Huang, K1
Hu, ZY1
Xie, Y1
Pati, S1
Houston, T1
Fassihi, SC1
Nabar, NR1
Fassihi, R1
Abrams-Downey, A1
Saabiye, J1
Vidaurrazaga, M1
Płusa, T1
Lengier-Krajewska, M1
Baranowska, A1
Krawczyk, J1
Mubagwa, K1
Fidahic, M1
Nujic, D1
Runjic, R1
Civljak, M1
Markotic, F1
Lovric Makaric, Z1
Puljak, L1
Timerbulatov, SV1
Timerbulstov, MV1
Gainullina, EN1
Gafarova, AR1
Timerbulatov, VM1
Wu, L1
O'Kane, AM1
Peng, H1
Bi, Y1
Motriuk-Smith, D1
Ren, J1
Kazama, I1
Iannaccone, G1
Scacciavillani, R1
Del Buono, MG1
Camilli, M1
Ronco, C1
Lavie, CJ1
Abbate, A1
Crea, F1
Massetti, M1
Aspromonte, N1
Million, M1
Roussel, Y1
Cirino, G1
Ahluwalia, A1
Guzman-Prado, Y1
Shehab, N1
Lovegrove, M1
Budnitz, DS2
Oscanoa, TJ1
Romero-Ortuno, R1
Carvajal, A1
Savarino, A2
Chen, X2
Geiger, JD1
Naghipour, S1
Ghodousi, M1
Rahsepar, S1
Elyasi, S1
Martinez, GP1
Zabaleta, ME1
Di Giulio, C1
Charris, JE1
Mijares, MR1
Biguetti, C1
Marrelli, MT1
Brotto, M1
Baud, FJ1
Megarbane, B1
Clemessy, JL1
Sachdev, U1
Ferrari, R1
Cui, X1
Pius, A1
Sahu, A1
Reynolds, M1
Liao, H1
Sun, P1
Shinde, S1
Ambrosio, F1
Shiva, S1
Loughran, P1
Scott, M1
Shang, Y1
Zhu, H1
Chen, G3
Liu, S1
Agostinis, P1
Rabson, A1
Melino, G2
Carafoli, E2
Sun, E1
Sharma, A1
Kumar Sharma, S1
Bucci, E1
Bhattacherjee, A1
Das, G1
Hou, Z1
Tu, S1
Hsia, BC1
Greige, N1
Quiroz, JA1
Khokhar, AS1
Daily, J1
Di Biase, L1
Ferrick, KJ1
Fisher, JD1
Krumerman, A1
Osama El-Gendy, A1
Saeed, H1
Ali, AMA1
Zawbaa, HM1
Gomaa, D1
Harb, HS1
Madney, YM1
Osama, H1
Abdelrahman, MA1
Abdelrahim, MEA1
Reuter, H1
Allwood, B1
Parker, A1
Koegelenberg, CFN1
Blockman, M1
Taljaard, J1
Kouzy, R1
Abi Jaoude, J1
Garcia Garcia, CJ1
El Alam, MB1
Taniguchi, CM1
Ludmir, EB1
Torres-Costa, S1
Lima-Fontes, M1
Falcão-Reis, F1
Falcão, M1
Belizário, JE1
Doboszewska, U1
Wlaź, P1
Nowak, G1
Młyniec, K1
Schrezenmeier, EV1
Burmester, GR1
Eckardt, KU1
Dörner, T1
Pizzorno, A1
Padey, B1
Dubois, J1
Julien, T1
Traversier, A1
Dulière, V1
Brun, P1
Lina, B1
Rosa-Calatrava, M1
Terrier, O1
Hazra, S1
Chaudhuri, AG1
Tiwary, BK1
Chakrabarti, N1
Iozzo, P1
Pillat, MM1
Krüger, A1
Guimarães, LMF1
Lameu, C1
de Souza, EE1
Wrenger, C1
Ulrich, H1
Jankowska, EA1
Sierpiński, R1
Tkaczyszyn, M1
Drozd, M1
Szachniewicz, J1
Duda-Sikuła, M1
Knysz, B1
Simon, K1
Szenborn, L1
Ponikowski, P1
Khuroo, MS1
Hoffmann, M1
Mösbauer, K1
Hofmann-Winkler, H1
Kaul, A1
Kleine-Weber, H1
Krüger, N1
Gassen, NC1
Müller, MA1
Drosten, C1
Pöhlmann, S1
Javorac, D1
Grahovac, L1
Manić, L1
Stojilković, N1
Anđelković, M1
Bulat, Z1
Đukić-Ćosić, D2
Curcic, M2
Djordjevic, AB1
Paliani, U1
Cardona, A1
Silva Arouche, TD1
Reis, AF1
Martins, AY1
S Costa, JF1
Carvalho Junior, RN1
J C Neto, AM1
Koren, G1
Korn, L1
Han, YJ1
Ren, ZG1
Li, XX1
Yan, JL1
Ma, CY1
Wu, DD1
Ji, XY1
Islam, M1
Gressier, F1
Verstuyft, C1
Becquemont, L1
Falissard, B1
Corruble, E1
Lebin, JA1
LeSaint, KT1
Braz, HLB1
Silveira, JAM1
Marinho, AD1
de Moraes, MEA1
Moraes Filho, MO1
Monteiro, HSA1
Jorge, RJB1
Mayayo-Vicente, S1
Rodriguez Salvanés, F1
Gallego-Arenas, A1
Sánchez-Gómez, LM1
Ruiz-López, M1
Sierra García, B1
Jurado-López, A1
Arriola-Bolado, P1
Cervera Cano, M1
Novella-Arribas, B1
Senna, G1
Caminati, M1
Castells, M1
Gao, G1
Wang, A1
Wang, S4
Qian, F1
Chen, M1
Yu, F1
Ma, X1
Zhao, T2
Chen, Z1
Zou, L1
Dai, L1
Vollaard, A1
Gieling, EM1
van der Linden, PD1
Sinha, B1
de Boer, MGJ1
Norinder, U1
Tuck, A1
Norgren, K1
Munic Kos, V1
Tarek, M1
Weston, S1
Coleman, CM1
Haupt, R1
Logue, J1
Matthews, K1
Reyes, HM1
Weiss, SR1
Frieman, MB1
De Franceschi, L1
Costa, E1
Dima, F1
Morandi, M1
Olivieri, O1
Gentile, D1
Fuochi, V1
Rescifina, A1
Furneri, PM1
Halm, MA1
Fadaka, AO1
Sibuyi, NRS1
Adewale, OB1
Bakare, OO1
Akanbi, MO1
Klein, A1
Madiehe, AM1
Meyer, M1
Podlasin, RB1
Kowalska, JD1
Pihowicz, A1
Wojtycha-Kwaśnica, B1
Thompson, M1
Dyda, T1
Czeszko-Paprocka, H1
Horban, A1
Uzunova, K1
Filipova, E1
Pavlova, V1
Vekov, T1
Calender, A1
Israel-Biet, D1
Valeyre, D1
Pacheco, Y1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Zhou, L3
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Xue, F1
Deng, L1
Yan, Z2
Meng, J1
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Ren, Y1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C4
Zhou, X2
Wang, W1
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Wu, X1
Li, W2
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C2
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Jung, YJ1
Koh, J1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S3
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liang, C1
Yang, H1
Song, Y1
Yu, K2
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Mu, W1
Gao, F2
Qi, Y1
Lu, H2
Cai, X1
Ji, RY1
Hou, Y4
Tian, J2
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Wu, D4
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z4
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D2
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K2
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Alexander, R1
Mondal, A1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y2
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H2
He, Z1
Wu, J1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Duong, F1
Kong, W1
Chang, JH1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y2
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J2
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Jeong, HJ1
Min, S1
Chae, H1
Lee, G1
Namgoong, SK1
Jeong, K1
Watanabe, LM1
Pires, IF1
Noronha, NY1
Pinhel, MAS1
Nonino, CB1
Moura-Neto, JA1
Misael, AM1
Silva, DRD1
D'Avila, R1
Andreoli, MCC1
Kraychete, A1
Bastos, K1
Nascimento, MMD1
Fatima, U1
Rizvi, SSA1
Fatima, S1
Hassan, MI1
Bull-Otterson, L1
Gray, EB1
Strosnider, HM1
Schieber, LZ1
Courtney, J1
García, MC1
Brooks, JT1
Mac Kenzie, WR1
Gundlapalli, AV1
Chan, XHS1
Cheah, PY1
Mo, L1
Zheng, P1
Guo, F1
Taleb, SJ1
Tong, M1
Shang, D1
Lei, ZN1
Wu, ZX1
Dong, S1
Yang, DH1
Ke, Z1
Chen, ZS1
Danjuma, MI1
Sinha, U1
Fatima, H1
Mohamed, MFH1
Nathoe, H1
Trevenzoli, M1
Guarnaccia, A1
Alberici, I1
Fassan, M1
Di Meco, E1
Farinati, F1
Cattelan, AM1
Baralić, K1
Jorgovanović, D1
Živančević, K1
Antonijević Miljaković, E1
Antonijević, B1
Buha Djordjevic, A1
Wang, N1
Han, S1
Liu, R2
Meng, L1
He, H1
Lv, Y1
Ding, Y1
Fu, J1
Lu, W1
Ma, W1
Zhan, Y1
Dai, B1
Jia, Q1
Ge, S1
Liang, P1
Hu, T1
Zhou, H1
Ta, W1
Lu, S1
He, L1
Fu, X1
Xie, C1
de Barros, CM1
Almeida, CAF1
Pereira, B1
Costa, KCM1
Pinheiro, FA1
Maia, LDB1
Trindade, CM1
Garcia, RCT1
Torres, LH1
Diwan, S1
Boralli, VB1
Jones, CW1
Woodford, AL1
Platts-Mills, TF1
Hushmandi, K1
Bokaie, S1
Hashemi, M1
Moghadam, ER1
Raei, M1
Hashemi, F1
Bagheri, M1
Nabavi, SM1
Kim, YS1
Lee, SY1
Yoon, JW1
Kim, D1
Yu, S1
Kim, JS1
Kim, JH1
Achutha, AS1
Pushpa, VL1
Suchitra, S1
Pereda, R1
Rivero, HB1
Rivero, JC1
Pérez, A1
López, LDR1
Mezquia, N1
Venegas, R1
Betancourt, JR1
Domínguez, RE1
Berling, I1
King, JD1
Shepherd, G1
Hoffman, RS1
Alhatali, B1
Lavergne, V1
Roberts, DM1
Gosselin, S1
Wilson, G1
Nolin, TD1
Ghannoum, M1
Alshaeri, HK1
Natto, ZS1
Perišić, O1
Zhang, XL1
Li, ZM1
Ye, JT1
Ye, LL1
Zhang, CX1
Liu, PQ1
Duan, DD1
Allam, MF1
Andraous, F1
Zhang, ZR1
Zhang, YN1
Li, XD1
Zhang, HQ1
Xiao, SQ1
Deng, F1
Yuan, ZM1
Ye, HQ1
Zhang, B1
Huang, YY1
Zhan, CG1
Luo, HB1
Mallhi, TH1
Ahmad, A1
Butt, MH1
Misbah, S1
Khan, YH1
Alotaibi, NH1
Niburski, K1
Niburski, O1
Pimentel, J1
Andersson, N1
Cohen, IV1
Makunts, T1
Moumedjian, T1
Issa, MA1
Abagyan, R1
Atakla, HG1
Noudohounsi, MMUD1
Sacca, H1
Tassiou, NRA1
Noudohounsi, WC1
Houinato, DS1
Mishra, SK1
Tripathi, T1
Yamoah, P1
Alalbila, TM1
Bangalee, V1
Oosthuizen, F1
Ogah, OS1
Umuerri, EM1
Adebiyi, A1
Orimolade, OA1
Sani, MU1
Ojji, DB1
Mbakwem, AC1
Stewart, S1
Sliwa, K1
Persoons, L1
Vanderlinden, E1
Vangeel, L1
Do, NDT1
Foo, SC1
Leyssen, P1
Jochmans, D1
Schols, D1
De Jonghe, S1
Liu, G1
Desforges, M1
Talbot, PJ1
Ding, N1
Lan, Y1
Lv, X1
Su, J1
He, W1
Keyaerts, E1
Vijgen, L1
Rysman, E1
Verbeeck, J1
Van Ranst, M1
Maes, P1

Clinical Trials (71)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883]Phase 2301 participants (Actual)Interventional2021-06-01Completed
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194]Phase 31,323 participants (Actual)Interventional2021-01-01Active, not recruiting
Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409]231 participants (Actual)Interventional2020-04-24Completed
An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231]100 participants (Anticipated)Interventional2021-04-26Recruiting
Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628]Phase 2452 participants (Actual)Interventional2020-06-01Completed
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial[NCT04339816]Phase 33 participants (Actual)Interventional2020-05-13Terminated (stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data)
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial[NCT04359095]Phase 2/Phase 3650 participants (Actual)Interventional2020-08-18Completed
Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467]Phase 23,217 participants (Actual)Interventional2020-03-28Completed
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349]Early Phase 1214 participants (Anticipated)Interventional2021-02-01Enrolling by invitation
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial[NCT04596839]Phase 260 participants (Actual)Interventional2020-09-04Completed
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260]152 participants (Actual)Interventional2021-03-18Completed
A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493]Phase 210 participants (Actual)Interventional2020-04-07Completed
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.[NCT04365725]84 participants (Actual)Observational2020-05-05Completed
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -[NCT04600999]Phase 314 participants (Actual)Interventional2020-10-07Completed
PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037]Phase 239 participants (Actual)Interventional2020-04-07Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.)
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870]500 participants (Anticipated)Observational2020-05-11Recruiting
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582]Phase 30 participants (Actual)Interventional2020-05-07Withdrawn (stopped due to The PI decided.)
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19[NCT04539873]Phase 3128 participants (Actual)Interventional2021-04-30Terminated (stopped due to non-inclusion of patients in the study effectively)
Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19[NCT04349592]456 participants (Actual)Interventional2020-04-14Completed
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study[NCT04463264]Phase 2/Phase 3135 participants (Anticipated)Interventional2020-06-26Recruiting
Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289]Phase 3147 participants (Actual)Interventional2020-05-01Terminated (stopped due to DSMB advise due to high probability of futility)
The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines[NCT05507671]Phase 3556 participants (Anticipated)Interventional2021-05-27Active, not recruiting
A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting[NCT04370782]Phase 418 participants (Actual)Interventional2020-04-28Completed
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh[NCT04402203]Phase 2/Phase 350 participants (Anticipated)Interventional2020-05-31Recruiting
Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019]Phase 2/Phase 31,930 participants (Anticipated)Interventional2020-09-30Not yet recruiting
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416]Phase 3204 participants (Anticipated)Interventional2020-06-02Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection[NCT04334512]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment[NCT04334967]Phase 413 participants (Actual)Interventional2020-03-30Suspended (stopped due to suspected unfavorable risk/benefit assessment)
Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725]80 participants (Anticipated)Observational2020-03-20Active, not recruiting
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271]Phase 2/Phase 33 participants (Actual)Interventional2020-04-17Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias)
Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994]Phase 3540 participants (Actual)Interventional2020-04-10Completed
Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients[NCT04443270]Phase 1200 participants (Anticipated)Interventional2020-07-27Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection[NCT04335084]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
"Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament ACAR en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes"[NCT04501965]Phase 2231 participants (Actual)Interventional2020-06-01Enrolling by invitation
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318]Phase 2/Phase 3100 participants (Anticipated)Interventional2020-05-31Not yet recruiting
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648]Phase 454 participants (Actual)Interventional2020-05-27Completed
Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications[NCT04502342]Phase 230 participants (Actual)Interventional2020-06-01Enrolling by invitation
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial[NCT04387760]Phase 2150 participants (Actual)Interventional2020-08-11Completed
Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia[NCT04654416]301 participants (Actual)Observational2020-03-20Completed
Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial[NCT04356534]40 participants (Actual)Interventional2020-04-19Completed
A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144]116 participants (Actual)Observational [Patient Registry]2020-05-02Completed
Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441]Phase 20 participants (Actual)Interventional2020-05-31Withdrawn (stopped due to Not started)
Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441]Phase 3624 participants (Actual)Interventional2020-04-07Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.)
Observational Study of COVID-19 Treatment Efficacy[NCT04369989]250 participants (Actual)Observational2020-04-14Terminated (stopped due to Review of data revealed poor correlation with hypothesis and data quality challenges.)
Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)[NCT04361526]40 participants (Anticipated)Interventional2020-04-17Recruiting
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial[NCT04438837]582 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial[NCT04344951]Phase 229 participants (Actual)Interventional2020-04-06Terminated (stopped due to No clinical efficacy against SARS-CoV-2 recorded)
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719]200 participants (Anticipated)Interventional2020-11-08Recruiting
Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study[NCT04471649]80 participants (Anticipated)Observational2020-06-15Recruiting
A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment[NCT04384380]33 participants (Actual)Interventional2020-04-01Completed
Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study[NCT04375709]60 participants (Anticipated)Observational2020-03-15Recruiting
Viral Kinetics of SARS-CoV-2 in Patients in the Intensive Care Unit Undergoing Dental Procedures[NCT05311410]60 participants (Anticipated)Interventional2021-09-20Recruiting
Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment[NCT04981379]Phase 31,120 participants (Actual)Interventional2020-11-16Completed
Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356]120 participants (Actual)Observational2020-11-19Completed
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic[NCT04540926]Phase 1/Phase 2200 participants (Anticipated)Interventional2020-09-30Not yet recruiting
Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144]200 participants (Anticipated)Observational2020-06-01Recruiting
Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534]1,800 participants (Actual)Observational2020-05-29Completed
Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851]23 participants (Anticipated)Observational2021-06-10Recruiting
Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328]Phase 3336 participants (Anticipated)Interventional2020-05-19Not yet recruiting
Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact[NCT04358614]Phase 2/Phase 312 participants (Actual)Interventional2020-03-16Completed
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593]Phase 2/Phase 3120 participants (Actual)Interventional2020-06-02Completed
Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial[NCT04392713]100 participants (Anticipated)Interventional2020-04-15Recruiting
Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.[NCT05045937]1,000 participants (Anticipated)Observational [Patient Registry]2022-05-01Recruiting
Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled[NCT04529525]Phase 2/Phase 3501 participants (Actual)Interventional2020-08-19Completed
Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients[NCT04472585]Phase 1/Phase 2180 participants (Anticipated)Interventional2020-11-14Recruiting
Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Therapeutic Safety of Ivermectin Versus Placebo Associated With Standard of Care Treatment in the Early Phase of Coronavirus Infection (COVID19).[NCT04836299]Phase 290 participants (Anticipated)Interventional2021-05-08Not yet recruiting
Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study[NCT04375202]Phase 2227 participants (Actual)Interventional2020-04-18Terminated (stopped due to Insufficient rate of patient accrual and newly available scientific evidence)
Evaluation of Awake Prone Positioning Effectiveness in Moderate to Severe COVID-19[NCT05083130]93 participants (Actual)Interventional2022-03-08Completed
Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial[NCT04323527]Phase 2278 participants (Actual)Interventional2020-03-23Completed
Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow[NCT05062681]Phase 460 participants (Anticipated)Interventional2021-09-15Recruiting
Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19[NCT04944082]Phase 460 participants (Anticipated)Interventional2021-07-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Count of Participants Who Died

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group0
Treatment Arm - Placebo Group0
Treatment Arm - Ivermectin Only Group0
Treatment Arm - Fluvoxamine Only Group0
Treatment Arm - Metformin and Fluvoxamine Group0
Treatment Arm - Metformin and Ivermectin Group1

Count of Participants With ED Visit, Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group27
Treatment Arm - Placebo Group48
Treatment Arm - Ivermectin Only Group16
Treatment Arm - Fluvoxamine Only Group15
Treatment Arm - Metformin and Fluvoxamine Group18
Treatment Arm - Metformin and Ivermectin Group23

Count of Participants With Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group8
Treatment Arm - Placebo Group18
Treatment Arm - Ivermectin Only Group5
Treatment Arm - Fluvoxamine Only Group5
Treatment Arm - Metformin and Fluvoxamine Group6
Treatment Arm - Metformin and Ivermectin Group4

Count of Participants With Hypoxia Only

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group147
Treatment Arm - Placebo Group158
Treatment Arm - Ivermectin Only Group88
Treatment Arm - Fluvoxamine Only Group73
Treatment Arm - Metformin and Fluvoxamine Group71
Treatment Arm - Metformin and Ivermectin Group96

Fever-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir16
Placebo Control Group17

Hospital-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

ICU-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Oxygen-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Time to Hospitalization Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir6
Placebo Control Group7

Time to Symptom Resolution: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir11
Placebo Control Group11

Vasopressor-free Days Through Study Day 29 (Group 2 and Placebo Control Group)

Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Ventilator-free Days: Day 1 to Day 29 (Group 2 and Placebo Control Group)

Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29

Interventiondays (Median)
Group 2 - Lopinavir/Ritonavir17
Placebo Control Group17

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)4
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)6
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Secondary Infection of Co-inhabitants of COVID-19 Positive PCR Patients in Self-quarantine

Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers:Rate of Hospitalization

if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Sub Study 2:Number of Health Care Workers Testing Positive at 2 Months

Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Substudy 1 - Number of COVID-19+ PCR Patients in Self-quarantine Who Are Hospitalized

Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers: Assessment of Any Medical Events That Occur During the ~60 Day Active Period

Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.

,
InterventionParticipants (Count of Participants)
moderate adverse eventsminor adverse events
Sub Study 2 Group 1 (HCQ)21
Sub Study 2 Group 2 (Placebo)00

Number of Participants Who Are Hospitalized for Covid 19 Infection

Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control0

Number of Participants Who Are Virus Free

Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial

Interventionparticipants (Number)
Treatment0
Control0

Number of Participants Who Die Secondary to Covid 19 Infection

Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)

InterventionParticipants (Count of Participants)
Treatment0
Control0

Number of Participants Who Discontinue or Withdraw Medication Use for Any Reason

Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control1

Number of Participants Who Have Confirmed Covid 19 Infection

Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment1
Control2

Number of Participants With Progression

After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days

InterventionParticipants (Count of Participants)
Standard of Care (SOC)5
Intervention Group11

Assess the Impact of Chronic Weight-based Dosing of HCQ for COVID-19 Prevention.

Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

Compare the Seroprevalence of SARS-CoV 2 IgM and/or IgG Positive Samples at Study Entry and Study Conclusion in All Participants Receiving HCQ Compared to Those Receiving Placebo.

Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2
Non-Randomized Active Comparator0

Comparison of the Emergence of Clinical Symptoms or COVID-19 Diagnosis in Participants Presenting Asymptomatically at Study Entry But Identified as Seropositive by Serology at Entry Between the Randomized Treatment Arms and Comparator Arm.

Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

Comparison of the Rate of SARS-CoV 2 Infections as Measured by IgM/IgG Seroconversion in Study Participants Receiving Randomized HCQ Versus Placebo.

Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2

Determine the Effect of Hydroxychloroquine Dose in the Prevention of COVID-19 Viremia and Disease.

Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1

Examine the Correlation Between HCQ Drug Levels and Development of COVID-19 Symptoms or Positive COVID-19 Test Results.

Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionCorrelation coefficient (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

Identify Immunologic, Serological and Inflammatory Markers Associated With Acquisition and Response to COVID-19 in Both HCQ and Placebo Participants Developing Laboratory or Clinical Confirmed Disease.

Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks

InterventionInflammatory markers (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

To Determine if the Use of Hydroxychloroquine as Preventive Therapy Decreases the Rate of Acquisition of SARS-CoV 2 Infections With Clinical COVID-19 Disease in Study Participants for Each Randomized Treatment Arm as Compared to Placebo.

The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

To Examine Other Clinical Factors Contributing to the Risk of SARS-CoV 2 Infection in Healthcare Workers and First Responders.

Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionClinical factors (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

To Examine the Level of Care Needed by Participants in Each Arm Developing COVID19 as Measured as Requiring Emergency Room Visit, Hospitalization or Able to Stay Home Without Hospital Care.

Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose0
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

Determine the Safety and Tolerability of HCQ Dosing for Preventive Strategy Against COVID-19 as Measured by Adverse Events and Serious Adverse Events.

Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

,,,
InterventionNumber of adverse events. (Number)
Adverse events (only Level 1 and 2) observed in the study.Serious adverse events (Level 3 or 4).
Non-Randomized Active Comparator20
Placebo1880
Study Drug - Daily Dose2060
Study Drug - Weekly Dose1930

Reviews

97 reviews available for chloroquine and Infections, Coronavirus

ArticleYear
Clinical trial analysis of 2019-nCoV therapy registered in China.
    Journal of medical virology, 2020, Volume: 92, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cli

2020
Of chloroquine and COVID-19.
    Antiviral research, 2020, Volume: 177

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infecti

2020
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
    World journal of pediatrics : WJP, 2020, Volume: 16, Issue:3

    Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
    Journal of critical care, 2020, Volume: 57

    Topics: Antimalarials; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus;

2020
Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology.
    Fa yi xue za zhi, 2020, Volume: 36, Issue:2

    Topics: Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fore

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
    Clinical immunology (Orlando, Fla.), 2020, Volume: 214

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir

2020
Emerging prophylaxis strategies against COVID-19.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Mar-30, Volume: 90, Issue:1

    Topics: Antiviral Agents; Betacoronavirus; Chemoprevention; Chloroquine; Clinical Trials as Topic; Coronavir

2020
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Pharmacotherapy, 2020, Volume: 40, Issue:5

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, Apr-27, Volume: 192, Issue:17

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe

2020
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect

2020
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    International journal of rheumatic diseases, 2020, Volume: 23, Issue:5

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19

2020
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    JAMA, 2020, May-12, Volume: 323, Issue:18

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists;

2020
COVID-19 and neuromuscular disorders.
    Neurology, 2020, 06-02, Volume: 94, Issue:22

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
Antiviral treatment of COVID-19
    Turkish journal of medical sciences, 2020, 04-21, Volume: 50, Issue:SI-1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru

2020
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
    Annales de cardiologie et d'angeiologie, 2020, Volume: 69, Issue:3

    Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis

2020
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:6

    Topics: Adult; Antimalarials; Child; Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; Huma

2020
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
    Journal of autoimmunity, 2020, Volume: 111

    Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroqu

2020
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure;

2020
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
    Pediatric rheumatology online journal, 2020, Apr-22, Volume: 18, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta

2020
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020, Volume: 39, Issue:7

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me

2020
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
    Journal of clinical epidemiology, 2020, Volume: 123

    Topics: Biomedical Research; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Obse

2020
Current status of potential therapeutic candidates for the COVID-19 crisis.
    Brain, behavior, and immunity, 2020, Volume: 87

    Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents, Non-Steroidal; A

2020
Treatment of SARS-CoV-2: How far have we reached?
    Drug discoveries & therapeutics, 2020, May-06, Volume: 14, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betac

2020
Cardiovascular manifestations and treatment considerations in COVID-19.
    Heart (British Cardiac Society), 2020, Volume: 106, Issue:15

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh

2020
COVID-19: Therapeutics and Their Toxicities.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2020, Volume: 16, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychl

2020
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2020, Volume: 27, Issue:6

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID

2020
Medical treatment options for COVID-19.
    European heart journal. Acute cardiovascular care, 2020, Volume: 9, Issue:3

    Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Human

2020
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.
    QJM : monthly journal of the Association of Physicians, 2020, 08-01, Volume: 113, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infectio

2020
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
    European heart journal. Acute cardiovascular care, 2020, Volume: 9, Issue:3

    Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus;

2020
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
    Archivos de la Sociedad Espanola de Oftalmologia, 2020, Volume: 95, Issue:6

    Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Co

2020
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2020, Volume: 59, Issue:2

    Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections;

2020
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
    Life sciences, 2020, Aug-01, Volume: 254

    Topics: Aminoquinolines; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavir

2020
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
    Acta medica portuguesa, 2020, Jul-01, Volume: 33, Issue:7-8

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir

2020
Should coronavirus disease 2019 concern rheumatologists?
    Polish archives of internal medicine, 2020, 08-27, Volume: 130, Issue:7-8

    Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans

2020
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
    Pharmacological research, 2020, Volume: 158

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
    Circulation. Arrhythmia and electrophysiology, 2020, Volume: 13, Issue:6

    Topics: Antimalarials; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-

2020
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
    Medicina, 2020, Volume: 80, Issue:3

    Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Cardiovascular Di

2020
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infecti

2020
[Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].
    Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control, 2020, Apr-22, Volume: 32, Issue:2

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pan

2020
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
    Journal of the American Heart Association, 2020, 06-16, Volume: 9, Issue:12

    Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart

2020
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:8

    Topics: Adult; Antiviral Agents; Betacoronavirus; Child; Chloroquine; Clinical Trials as Topic; Coronavirus

2020
The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
    Arquivos brasileiros de cardiologia, 2020, 06-01, Volume: 114, Issue:5

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Animals; Antirheumatic Agents; An

2020
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 07-06, Volume: 192, Issue:27

    Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
    Clinical rheumatology, 2020, Volume: 39, Issue:8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
    Postgraduate medicine, 2020, Volume: 132, Issue:7

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 229E, H

2020
A current review of COVID-19 for the cardiovascular specialist.
    American heart journal, 2020, Volume: 226

    Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card

2020
Coronavirus Disease 2019: Clinical Review.
    Acta medica portuguesa, 2020, Jul-01, Volume: 33, Issue:7-8

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus;

2020
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    In vivo (Athens, Greece), 2020, Volume: 34, Issue:3 Suppl

    Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Beta

2020
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
    Advances in rheumatology (London, England), 2020, 06-09, Volume: 60, Issue:1

    Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine;

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Lithium and coronaviral infections. A scoping review.
    F1000Research, 2020, Volume: 9

    Topics: Animals; Betacoronavirus; Cells, Cultured; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
    Virus research, 2020, Volume: 286

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cor

2020
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
    European urology focus, 2020, Sep-15, Volume: 6, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral

2020
Chloroquine in controlling biological infections.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2020, Jun-17, Volume: 48, Issue:285

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Cardiac effects and toxicity of chloroquine: a short update.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pan

2020
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
    Khirurgiia, 2020, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In

2020
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
    Biochemical pharmacology, 2020, Volume: 178

    Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral

2020
Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
    Drug discoveries & therapeutics, 2020, Jul-15, Volume: 14, Issue:3

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Drug Delive

2020
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Cardiorenal medicine, 2020, Volume: 10, Issue:5

    Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis

2020
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autopha

2020
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Expert review of anti-infective therapy, 2020, Volume: 18, Issue:11

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Dru

2020
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
    Current pharmaceutical design, 2020, Volume: 26, Issue:35

    Topics: Autoimmune Diseases; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy

2020
Is hydroxychloroquine beneficial for COVID-19 patients?
    Cell death & disease, 2020, 07-08, Volume: 11, Issue:7

    Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chlor

2020
Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.
    Current drug metabolism, 2020, Volume: 21, Issue:7

    Topics: Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections;

2020
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
    JAMA network open, 2020, 07-01, Volume: 3, Issue:7

    Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimala

2020
SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice.
    Acta medica portuguesa, 2020, Sep-01, Volume: 33, Issue:9

    Topics: Aged; Antiviral Agents; Betacoronavirus; Chloroquine; Conjunctiva; Conjunctivitis, Viral; Coronaviru

2020
Targeting zinc metalloenzymes in coronavirus disease 2019.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzymes; Hu

2020
Role for antimalarials in the management of COVID-19.
    Current opinion in rheumatology, 2020, Volume: 32, Issue:5

    Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVI

2020
Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
    Life sciences, 2020, Sep-15, Volume: 257

    Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Chloroquine; Computational Biolo

2020
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
    Journal of critical care, 2020, Volume: 59

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2020, Volume: 97, Issue:9

    Topics: Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVI

2020
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic;

2020
An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2020, Volume: 144

    Topics: Animals; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; D

2020
Advances and challenges in the prevention and treatment of COVID-19.
    International journal of medical sciences, 2020, Volume: 17, Issue:12

    Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coro

2020
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
    The western journal of emergency medicine, 2020, Jun-03, Volume: 21, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment].
    Semergen, 2020, Volume: 46 Suppl 1

    Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Uncertaint

2020
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
    Archives of pharmacal research, 2020, Volume: 43, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydro

2020
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 130

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Che

2020
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2020, 11-01, Volume: 29, Issue:6

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Heart Diseases; Hospi

2020
Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.
    The Journal of international medical research, 2020, Volume: 48, Issue:8

    Topics: Adenosine Monophosphate; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents;

2020
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavir

2020
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
    Trends in immunology, 2020, Volume: 41, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Autophagy; Azithromycin; Betacoronavirus; Chloroquine; Cor

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:10

    Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronav

2020
Traditional Chinese Medicine as Potential Therapy for COVID-19.
    The American journal of Chinese medicine, 2020, Volume: 48, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agen

2020
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
    Pharmacology & therapeutics, 2020, Volume: 216

    Topics: Animals; Antimalarials; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Corona

2020
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    Pain physician, 2020, Volume: 23, Issue:4S

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
A review of medications used to control and improve the signs and symptoms of COVID-19 patients.
    European journal of pharmacology, 2020, Nov-15, Volume: 887

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19

2020
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
    Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:10

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychlor

2020
A contemporary look at COVID-19 medications: available and potentially effective drugs.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17

    Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacor

2020
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
    Acta pharmacologica Sinica, 2020, Volume: 41, Issue:11

    Topics: Antiviral Agents; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 D

2020
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:10

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Chloroquine and its derivatives in the management of COVID-19: A scoping review
    Biomedica : revista del Instituto Nacional de Salud, 2020, 10-30, Volume: 40, Issue:Supl. 2

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials;

2020
One year update on the COVID-19 pandemic: Where are we now?
    Acta tropica, 2021, Volume: 214

    Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as

2021
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
    Global heart, 2021, 03-15, Volume: 16, Issue:1

    Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor

2021

Trials

6 trials available for chloroquine and Infections, Coronavirus

ArticleYear
Treating COVID-19 with Chloroquine.
    Journal of molecular cell biology, 2020, 05-18, Volume: 12, Issue:4

    Topics: Adult; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lo

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroq

2020
An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication.
    European journal of clinical investigation, 2020, Volume: 50, Issue:7

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
    Trials, 2020, Jul-08, Volume: 21, Issue:1

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therap

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
[Chloroquine phosphate: therapeutic drug for COVID-19].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020, Apr-30, Volume: 40, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr

2020

Other Studies

171 other studies available for chloroquine and Infections, Coronavirus

ArticleYear
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop

2020
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
    Clinical pharmacology and therapeutics, 2022, Volume: 112, Issue:4

    Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DN

2022
Comparison of the Antiviral Activity of Remdesivir, Chloroquine, and Interferon-β as Single or Dual Agents Against the Human Beta-Coronavirus OC43.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2023, Volume: 43, Issue:1

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; Coronavirus OC43, Human; Humans; Interferon-b

2023
Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice.
    Antiviral research, 2020, Volume: 173

    Topics: Animals; Antiviral Agents; Brain; Central Nervous System; Chloroquine; Coronavirus Infections; Coron

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
    Cell research, 2020, Volume: 30, Issue:3

    Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi

2020
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:3

    Topics: Animals; Betacoronavirus; Chiroptera; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19 Dru

2020
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:3

    Topics: Animals; Betacoronavirus; Chiroptera; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19 Dru

2020
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:3

    Topics: Animals; Betacoronavirus; Chiroptera; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19 Dru

2020
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:3

    Topics: Animals; Betacoronavirus; Chiroptera; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19 Dru

2020
More than 80 clinical trials launch to test coronavirus treatments.
    Nature, 2020, Volume: 578, Issue:7795

    Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Cli

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
    Bioscience trends, 2020, Mar-16, Volume: 14, Issue:1

    Topics: Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COV

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2020, Mar-12, Volume: 43, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; China; Chloroquine; Consensus; Coronavirus Infections; COVI

2020
    Revue medicale suisse, 2020, Mar-11, Volume: 16, Issue:685

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pandemics;

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Evaluation, P

2020
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Advance of promising targets and agents against COVID-19 in China.
    Drug discovery today, 2020, Volume: 25, Issue:5

    Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus;

2020
Insights from nanomedicine into chloroquine efficacy against COVID-19.
    Nature nanotechnology, 2020, Volume: 15, Issue:4

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 07-28, Volume: 71, Issue:15

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID

2020
Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2020, Volume: 19, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus

2020
Chloroquine and COVID-19, where do we stand?
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Pandemics;

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Race to find COVID-19 treatments accelerates.
    Science (New York, N.Y.), 2020, 03-27, Volume: 367, Issue:6485

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin

2020
Chloroquine in COVID-19: the evidence.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Mar-31, Volume: 90, Issue:1

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
    Annals of internal medicine, 2020, 06-02, Volume: 172, Issue:11

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi

2020
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
    Rheumatology international, 2020, Volume: 40, Issue:5

    Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Betacoronavirus; Chloroquine;

2020
Combating COVID-19 with Chloroquine.
    Journal of molecular cell biology, 2020, 05-18, Volume: 12, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Endocytosis; Huma

2020
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.
    Annals of the rheumatic diseases, 2020, Volume: 79, Issue:5

    Topics: Adenosine Monophosphate; Alanine; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus; Coronavi

2020
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:5

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatme

2020
COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
    American journal of ophthalmology, 2020, Volume: 213

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; H

2020
What is the role of rheumatologists in the era of COVID-19?
    Autoimmunity reviews, 2020, Volume: 19, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir

2020
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:5

    Topics: Amino Acid Sequence; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy

2020
Chloroquine for COVID-19 Infection.
    Drug safety, 2020, Volume: 43, Issue:5

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pan

2020
Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.
    Revista da Sociedade Brasileira de Medicina Tropical, 2020, Volume: 53

    Topics: Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; Humans; P

2020
Chloroquine and hydroxychloroquine in covid-19.
    BMJ (Clinical research ed.), 2020, 04-08, Volume: 369

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; CO

2020
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
    Nature medicine, 2020, Volume: 26, Issue:5

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fear; Human

2020
Can prophylactic drugs keep fragile health systems running?
    Science (New York, N.Y.), 2020, 04-10, Volume: 368, Issue:6487

    Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine;

2020
Regulators split on antimalarials for COVID-19.
    Lancet (London, England), 2020, 04-11, Volume: 395, Issue:10231

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Approval; Europe

2020
G6PD and chloroquine: Selecting the treatment against SARS-CoV-2?
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:9

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Glucosephosphate Dehy

2020
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Bioscience trends, 2020, May-21, Volume: 14, Issue:2

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Drug Evaluation during the Covid-19 Pandemic.
    The New England journal of medicine, 2020, Jun-11, Volume: 382, Issue:24

    Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D

2020
Chloroquine as a prophylactic agent against COVID-19?
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Animals; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Chlor

2020
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infec

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:10

    Topics: Betacoronavirus; Chloroquine; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Drug Treat

2020
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
    Molecules (Basel, Switzerland), 2020, Apr-16, Volume: 25, Issue:8

    Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine;

2020
Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation.
    Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2

    Topics: Adult; Antiviral Agents; Body Weight; Child; Child, Preschool; Chloroquine; Coronavirus Infections;

2020
Is GSK3β a molecular target of chloroquine treatment against COVID-19?
    Drug discoveries & therapeutics, 2020, May-06, Volume: 14, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; C

2020
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:6

    Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; C

2020
Some drugs for COVID-19.
    The Medical letter on drugs and therapeutics, 2020, 04-06, Volume: 62, Issue:1595

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiote

2020
Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.
    Drug discovery today, 2020, Volume: 25, Issue:6

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aquatic Organisms; Biological Products; Chloroqu

2020
Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.
    JAMA network open, 2020, 04-24, Volume: 3, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu

2020
Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.
    Annals of clinical microbiology and antimicrobials, 2020, Apr-24, Volume: 19, Issue:1

    Topics: Adult; Betacoronavirus; Chloroquine; Clarithromycin; Colombia; Coronavirus Infections; COVID-19; COV

2020
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
    Archives of cardiovascular diseases, 2020, Volume: 113, Issue:5

    Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1

2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations;

2020
Chloroquine hype is derailing the search for coronavirus treatments.
    Nature, 2020, Volume: 580, Issue:7805

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene.
    Clinical chemistry and laboratory medicine, 2020, 06-25, Volume: 58, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Female; Glucosephosphate Dehydrogena

2020
COVID-19: an update on diagnostic and therapeutic approaches.
    BMB reports, 2020, Volume: 53, Issue:4

    Topics: Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVI

2020
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020, Volume: 20, Issue:7

    Topics: Adult; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combin

2020
Thoughts on COVID-19 and autoimmune diseases.
    Lupus science & medicine, 2020, Volume: 7, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co

2020
Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
    Medical hypotheses, 2020, Volume: 140

    Topics: Africa South of the Sahara; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Antiviral

2020
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Circulation. Arrhythmia and electrophysiology, 2020, Volume: 13, Issue:6

    Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroqui

2020
Internet Searches for Unproven COVID-19 Therapies in the United States.
    JAMA internal medicine, 2020, 08-01, Volume: 180, Issue:8

    Topics: Betacoronavirus; Chloroquine; Consumer Health Information; Coronavirus Infections; COVID-19; COVID-1

2020
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
    European heart journal. Cardiovascular pharmacotherapy, 2020, 07-01, Volume: 6, Issue:4

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections;

2020
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:6

    Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr

2020
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
    European journal of clinical investigation, 2020, Volume: 50, Issue:6

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec

2020
COVID-19 and Depression.
    Clinical therapeutics, 2020, Volume: 42, Issue:6

    Topics: Anxiety; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Depression; Humans; Hydroxy

2020
[Potential harms associated with 4-aminoquinoline treatment].
    Lakartidningen, 2020, 04-23, Volume: 117

    Topics: Aminoquinolines; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infectio

2020
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020, 05-04, Volume: 192, Issue:18

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pa

2020
The COVID-19 Pandemic and Mayo Clinic Proceedings.
    Mayo Clinic proceedings, 2020, Volume: 95, Issue:5

    Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2020
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
    Drug discovery today, 2020, Volume: 25, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi

2020
COVID-19: an unexpected indication for anti-rheumatic therapies?
    Rheumatology (Oxford, England), 2020, 06-01, Volume: 59, Issue:6

    Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Ch

2020
COVID-19 and toxicity from potential treatments: Panacea or poison.
    Emergency medicine Australasia : EMA, 2020, Volume: 32, Issue:4

    Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVI

2020
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
    Heart rhythm, 2020, Volume: 17, Issue:9

    Topics: Aged, 80 and over; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; CO

2020
Chloroquine for COVID-19: rationale, facts, hopes.
    Critical care (London, England), 2020, May-08, Volume: 24, Issue:1

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus

2020
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
    The Annals of pharmacotherapy, 2020, Volume: 54, Issue:8

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Emergencies

2020
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:2

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Computational Biology; Coronavirus Infections; COVID

2020
Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.
    American journal of hematology, 2020, Volume: 95, Issue:8

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephos

2020
[Chloroquine as a possible treatment for COVID-19].
    Nederlands tijdschrift voor geneeskunde, 2020, Mar-11, Volume: 164

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect

2020
Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
    Respirology (Carlton, Vic.), 2020, Volume: 25, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroqu

2020
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
    NTM, 2020, Volume: 28, Issue:2

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine;

2020
In Vitro Data of Current Therapies for SARS-CoV-2.
    Current medicinal chemistry, 2020, Volume: 27, Issue:27

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID

2020
Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1

    Topics: Betacoronavirus; Cameroon; Chloroquine; Chromatography, High Pressure Liquid; Chromatography, Thin L

2020
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 D

2020
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
    Medical hypotheses, 2020, Volume: 142

    Topics: Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dieta

2020
Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Animals; Arrhythmias, Cardiac; Benzodiazepinones; Cardiotoxicity; Chloroquine; Clonazepam; Coronavir

2020
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1).
    Annals of internal medicine, 2020, 07-21, Volume: 173, Issue:2

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans;

2020
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:9

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
    Medicina intensiva, 2020, Volume: 44, Issue:8

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-

2020
Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
    JAMA internal medicine, 2020, 09-01, Volume: 180, Issue:9

    Topics: Access to Information; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19

2020
Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.
    Kidney international, 2020, Volume: 98, Issue:1

    Topics: Acute Kidney Injury; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Crit

2020
5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
    Medical hypotheses, 2020, Volume: 142

    Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronaviru

2020
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
    American journal of ophthalmology, 2020, Volume: 216

    Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topi

2020
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
    The primary care companion for CNS disorders, 2020, 05-21, Volume: 22, Issue:3

    Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd

2020
COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?
    Journal of infection and public health, 2020, Volume: 13, Issue:6

    Topics: Antimalarials; Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indi

2020
Navigating COVID-19 in the developing world.
    Clinical rheumatology, 2020, Volume: 39, Issue:7

    Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of He

2020
Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
    JAMA, 2020, 06-23, Volume: 323, Issue:24

    Topics: Antihypertensive Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Utiliz

2020
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant].
    Revue des maladies respiratoires, 2020, Volume: 37, Issue:6

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Betacoronavirus;

2020
Death threats after a trial on chloroquine for COVID-19.
    The Lancet. Infectious diseases, 2020, Volume: 20, Issue:6

    Topics: Betacoronavirus; Brazil; Chloroquine; Clinical Trials, Phase II as Topic; Coronavirus Infections; CO

2020
Safety fears over drug hyped to treat the coronavirus spark global confusion.
    Nature, 2020, Volume: 582, Issue:7810

    Topics: Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Global Health; Humans; Hydr

2020
Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
    Medical hypotheses, 2020, Volume: 143

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Resist

2020
COVID-19 presenting with diarrhoea and hyponatraemia.
    BMJ case reports, 2020, Jun-07, Volume: 13, Issue:6

    Topics: Abdominal Pain; Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus In

2020
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
    Archivos de cardiologia de Mexico, 2020, Volume: 90, Issue:Supl

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19;

2020
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Culture; Endp

2020
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
    Journal of the neurological sciences, 2020, 08-15, Volume: 415

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Living evidence in response to controversies about the use of antimalarials in COVID-19.
    Revista espanola de cardiologia (English ed.), 2020, Volume: 73, Issue:8

    Topics: Antimalarials; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Pandemics;

2020
Potential of Flavonoid-Inspired Phytomedicines against COVID-19.
    Molecules (Basel, Switzerland), 2020, Jun-11, Volume: 25, Issue:11

    Topics: Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroqu

2020
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Annals of internal medicine, 2020, 07-21, Volume: 173, Issue:2

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Treatment strategies of hospitalized patients with coronavirus disease-19.
    Aging, 2020, 06-17, Volume: 12, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquin

2020
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
    Epilepsy research, 2020, Volume: 165

    Topics: Adolescent; Adult; Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr

2020
Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
    British journal of pharmacology, 2020, Volume: 177, Issue:21

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Delive

2020
Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19.
    BMC medical research methodology, 2020, 06-22, Volume: 20, Issue:1

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infecti

2020
Chloroquine and COVID-19: A western medical and scientific drift?
    European journal of internal medicine, 2020, Volume: 78

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
    British journal of pharmacology, 2020, Volume: 177, Issue:15

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine;

2020
Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
    The American journal of cardiology, 2020, 09-01, Volume: 130

    Topics: Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment

2020
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
    JAMA internal medicine, 2020, 10-01, Volume: 180, Issue:10

    Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19;

2020
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
    Cellular signalling, 2020, Volume: 73

    Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cyt

2020
Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
    Revista de saude publica, 2020, Volume: 54

    Topics: Antimalarials; Betacoronavirus; Chloroquine; Contraindications, Drug; Coronavirus Infections; COVID-

2020
Concentration-dependent mortality of chloroquine in overdose.
    eLife, 2020, 07-08, Volume: 9

    Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru

2020
Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.
    Molecular medicine (Cambridge, Mass.), 2020, 07-08, Volume: 26, Issue:1

    Topics: Animals; Autophagosomes; Autophagy; Betacoronavirus; Caspase 1; Caspases, Initiator; Chloroquine; Co

2020
BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
    Cell death & disease, 2020, 07-08, Volume: 11, Issue:7

    Topics: Africa; Antiviral Agents; BCG Vaccine; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-1

2020
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2020, Volume: 59, Issue:2

    Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Inf

2020
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
    Vaccine, 2020, 07-31, Volume: 38, Issue:35

    Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19

2020
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, 04-02, Volume: 110, Issue:5

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: BCG Vaccine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-1

2020
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral research, 2020, Volume: 181

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Berberine; Betacoronavirus; Chlorocebus

2020
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
    Kardiologia polska, 2020, 08-25, Volume: 78, Issue:7-8

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
    Nature, 2020, Volume: 585, Issue:7826

    Topics: Animals; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVI

2020
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
    European journal of internal medicine, 2020, Volume: 80

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Journal of nanoscience and nanotechnology, 2020, 12-01, Volume: 20, Issue:12

    Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Bin

2020
Chloroquine for Covid 19: introducing drug repurposing to medical students.
    International journal of medical education, 2020, Jul-24, Volume: 11

    Topics: Chloroquine; Coronavirus Infections; COVID-19; Drug Repositioning; Education, Medical; Humans; Pande

2020
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:6

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Psychiatric Side Effects of Chloroquine.
    The Journal of clinical psychiatry, 2020, 07-28, Volume: 81, Issue:5

    Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Mental Disorders

2020
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
    Annals of internal medicine, 2020, 09-01, Volume: 173, Issue:5

    Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus;

2020
Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic.
    Current opinion in allergy and clinical immunology, 2020, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Anaphylaxis; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents,

2020
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
    Journal of acquired immune deficiency syndromes (1999), 2020, 10-01, Volume: 85, Issue:2

    Topics: Adult; Antimalarials; Chloroquine; Chronic Disease; Coronavirus Infections; COVID-19; Drug Combinati

2020
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
    Nederlands tijdschrift voor geneeskunde, 2020, 06-02, Volume: 164

    Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-

2020
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
    European journal of drug metabolism and pharmacokinetics, 2020, Volume: 45, Issue:6

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Journal of virology, 2020, 10-14, Volume: 94, Issue:21

    Topics: A549 Cells; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coronavirus Inf

2020
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.
    European journal of internal medicine, 2020, Volume: 80

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glucosephos

2020
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
    International journal of molecular sciences, 2020, Aug-14, Volume: 21, Issue:16

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Envelope Proteins; Coronavirus Infection

2020
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
    Annals of internal medicine, 2020, 10-06, Volume: 173, Issue:7

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hyd

2020
How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.
    European journal of medical research, 2020, Aug-27, Volume: 25, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus In

2020
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
    Scientific reports, 2020, 08-31, Volume: 10, Issue:1

    Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Disco

2020
The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19.
    Clinics (Sao Paulo, Brazil), 2020, Volume: 75

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Obe

2020
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
    Jornal brasileiro de nefrologia, 2020, Aug-26, Volume: 42, Issue:2 suppl 1

    Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Human

2020
Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.
    MMWR. Morbidity and mortality weekly report, 2020, Sep-04, Volume: 69, Issue:35

    Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Ma

2020
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
    PLoS medicine, 2020, Volume: 17, Issue:9

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea

2020
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
    European journal of clinical investigation, 2020, Volume: 50, Issue:11

    Topics: Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans;

2020
SARS-CoV-2 and hepatitis.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, Sep-09, Volume: 29, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Chemical and D

2020
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
    Toxicology and applied pharmacology, 2020, 11-01, Volume: 406

    Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infec

2020
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2020, Volume: 79

    Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Autophagy; Betacoronaviru

2020
Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
    Medicine, 2020, Sep-11, Volume: 99, Issue:37

    Topics: Anti-Infective Agents; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19;

2020
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
    BMJ open, 2020, 09-17, Volume: 10, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Cli

2020
Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.
    BMB reports, 2020, Volume: 53, Issue:10

    Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Cell Differentiation

2020
Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
    Journal of proteome research, 2020, 11-06, Volume: 19, Issue:11

    Topics: Betacoronavirus; Catalytic Domain; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO

2020
Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; Child, Prescho

2020
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
    Biomolecules, 2020, 09-21, Volume: 10, Issue:9

    Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibo

2020
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
    Central European journal of public health, 2020, Volume: 28, Issue:3

    Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therap

2020
A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2.
    Signal transduction and targeted therapy, 2020, 10-03, Volume: 5, Issue:1

    Topics: Animals; Antiviral Agents; Betacoronavirus; Biological Products; Bufanolides; Cardiac Glycosides; Ce

2020
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 11-03, Volume: 117, Issue:44

    Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO

2020
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
    Annals of internal medicine, 2020, 12-01, Volume: 173, Issue:11

    Topics: Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics;

2020
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
    Journal of medical Internet research, 2020, 11-20, Volume: 22, Issue:11

    Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections;

2020
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
    Scientific reports, 2020, 11-05, Volume: 10, Issue:1

    Topics: Chloroquine; Cohort Studies; Coronavirus Infections; COVID-19; Female; Heart; Humans; Hydroxychloroq

2020
Acute Guillain-Barré polyradiculoneuritis indicative of COVID-19 infection: a case report.
    The Pan African medical journal, 2020, Volume: 35, Issue:Suppl 2

    Topics: Adult; Atrial Fibrillation; Azithromycin; Betacoronavirus; Chloroquine; Clinical Laboratory Techniqu

2020
Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion.
    Therapeutic innovation & regulatory science, 2020, Volume: 54, Issue:6

    Topics: Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatme

2020
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
    Antiviral research, 2021, Volume: 193

    Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Coronavirus; Coronaviru

2021
Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9

    Topics: Antiviral Agents; Cell Line; Chloroquine; Coronavirus Infections; Coronavirus OC43, Human; Genes, Re

2016
Induction of Atypical Autophagy by Porcine Hemagglutinating Encephalomyelitis Virus Contributes to Viral Replication.
    Frontiers in cellular and infection microbiology, 2017, Volume: 7

    Topics: Adenine; Animals; Autophagosomes; Autophagy; Betacoronavirus 1; Cell Line; Cell Survival; Chloroquin

2017
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8

    Topics: Animals; Animals, Newborn; Antiviral Agents; Cell Line, Tumor; Cell Survival; Chloroquine; Coronavir

2009